文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2020 年 4 月 6 日，意大利伦巴第大区洛迪红区献血者中 SARS-CoV-2 特异性中和抗体的流行情况。

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.

机构信息

Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy.

Immunohematology and Transfusion Medicine Unit, Ospedale Maggiore di Lodi, Lodi, Italy.

出版信息

Euro Surveill. 2020 Jun;25(24). doi: 10.2807/1560-7917.ES.2020.25.24.2001031.

DOI:10.2807/1560-7917.ES.2020.25.24.2001031
PMID:32583766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7315724/
Abstract

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 - when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19-70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.

摘要

我们评估了居住在意大利洛迪红区的献血者（BD）中的 SARS-CoV-2 RNA 和中和抗体。在 2020 年 2 月 20 日（伦巴第大区首例 COVID-19 病例确诊）之后招募的 390 名 BD 中，91 名（23%）年龄在 19-70 岁的人抗体呈阳性。另外 17 名（4.3%）BD 的病毒 RNA 检测呈阳性，因此约有 28%（108/390）的人有病毒暴露的证据。早在 2 月 12 日就采集的 5 份储存样本血清学呈阳性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/aa441d9357f6/2001031-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/aa441d9357f6/2001031-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c02/7315724/3a0ce1cd7c83/2001031-f2.jpg

相似文献

[1]
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.

Euro Surveill. 2020-6

[2]
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.

Euro Surveill. 2020-7

[3]
Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.

Euro Surveill. 2020-11

[4]
A serological assay to detect SARS-CoV-2 seroconversion in humans.

Nat Med. 2020-5-12

[5]
Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.

Clin Microbiol Infect. 2021-6

[6]
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.

Euro Surveill. 2020-10

[7]
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.

J Infect Dis. 2020-10-13

[8]
Antibody-based therapies for COVID-19: Can Europe move faster?

PLoS Med. 2020-5-5

[9]
COVID-19: Main therapeutic options.

Tunis Med. 2020-4

[10]
Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic.

Clin Lab. 2020-10-1

引用本文的文献

[1]
The Long-Term Immunity of a Microneedle Array Patch of a SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice.

Vaccines (Basel). 2025-1-18

[2]
Fourth dose of microneedle array patch of SARS-CoV-2 S1 protein subunit vaccine elicits robust long-lasting humoral responses in mice.

Int Immunopharmacol. 2024-3-10

[3]
Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.

BMJ Open. 2023-11-6

[4]
Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).

Eur J Public Health. 2023-10-10

[5]
Overview of SARS-COV-2 infection at the Butantan Penitentiary Progression Center.

Rev Saude Publica. 2023

[6]
A Pilot Study on Blood Components in COVID-19 Affected Subjects: A Correlation to UPR Signalling and ER-Stress.

Indian J Clin Biochem. 2023-7

[7]
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.

Microbiol Spectr. 2023-6-15

[8]
Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.

PLoS One. 2023

[9]
19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern.

iScience. 2023-4-21

[10]
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.

Int J Mol Sci. 2023-4-4

本文引用的文献

[1]
Challenges of Convalescent Plasma Therapy on COVID-19.

J Clin Virol. 2020-6

[2]
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.

J Med Virol. 2020-6-29

[3]
COVID-19: Herd immunity and convalescent plasma transfer therapy.

J Med Virol. 2020-9

[4]
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.

J Korean Med Sci. 2020-4-13

[5]
Deployment of convalescent plasma for the prevention and treatment of COVID-19.

J Clin Invest. 2020-6-1

[6]
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.

Proc Natl Acad Sci U S A. 2020-4-6

[7]
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?

Vox Sang. 2020-5-3

[8]
Coronavirus Disease 2019 (COVID-19) in Italy.

JAMA. 2020-4-14

[9]
West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors.

Viruses. 2020-1-29

[10]
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Euro Surveill. 2020-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索